CFB-Targeting RNAi Oligonucleotides for Complement Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods to inhibit or silence complement factor B (CFB) to treat diseases associated with complement pathway activation or dysregulation, such as paroxysmal nocturnal hemoglobinuria, multiple sclerosis, and rheumatoid arthritis.
Innovation Solution
RNAi oligonucleotides targeting CFB mRNA are developed, comprising a sense and antisense strand with specific nucleotide sequences and modifications, including 2′-O-methyl and 2′-fluoro ribonucleosides, to reduce CFB expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement factor B (CFB) is inhibited to treat diseases associated with complement pathway activation, then therapeutic benefit is improved, but CFB expression reduction must be achieved through complex RNAi oligonucleotide designs
Solution Approach 1:
The oligonucleotide is divided into distinct functional regions: a guide strand complementary to CFB mRNA, a passenger strand, and specific modifications at defined positions. This segmentation allows independent optimization of each region for target recognition, stability, and efficacy, resolving the complexity of designing a fully functional inhibitory molecule.
Solution Approach 2:
The patent applies specific chemical modifications (2′-O-methyl, 2′-fluoro) at predetermined positions in the oligonucleotide sequence. These parameter changes modify the physical and chemical properties of the oligonucleotide to enhance stability, reduce immunogenicity, and improve cellular uptake, thereby achieving reliable therapeutic effect without requiring overly complex sequence designs.
2Quantity of substance
If RNAi oligonucleotides are used to reduce CFB expression, then CFB levels in blood are lowered, but the oligonucleotides must undergo extensive metabolic processing and clearance
Solution Approach 1:
The patent employs a passenger strand as an intermediary element that forms a duplex with the guide strand. This duplex structure protects the guide strand from rapid degradation by nucleases, thereby extending the half-life of the oligonucleotide in circulation. The passenger strand acts as a protective intermediary that enables sustained CFB expression reduction over time.
Solution Approach 2:
The oligonucleotide is designed with modifications that facilitate controlled degradation and renal clearance. By incorporating specific nucleotide sequences and chemical modifications, the molecule achieves sufficient half-life for therapeutic effect while maintaining efficient elimination pathways, avoiding accumulation and toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi oligonucleotides effectively reduce CFB expression by up to 100% in cells and lower circulating CFB levels in the blood, providing therapeutic benefits for diseases mediated by complement pathway dysregulation.
Implementation Method 1
The antisense strand of the oligonucleotide includes a region of complementarity to a CFB mRNA target sequence
Implementation Method 2
modifications, including 2′-O-methyl and 2′-fluoro ribonucleosides
Data Source
AI summary
Described herein are oligonucleotides (e.g., RNAi oligonucleotides) containing sense and antisense strands for targeting complement factor B (CFB) mRNA. The RNAi oligonucleotide may be used to inhibit CFB expression, levels, and/or activity in a cell. Also, described herein are methods for using an oligonucleotide (e.g., an RNAi oligonucleotide) for the prophylaxis or treatment of a disease, disorder, or condition mediated by complement pathway activation or dysregulation.